For citations:
Nasonov E.L., Mazurov V.I., Zonova E.V., Knyazeva L.A., Marusenko I.M., Nesmeyanova O.B., Plaksina T.V., Shapovalova Yu.S., Ilivanova E.P., Krechikova D.G., Petrochenkova N.A., Reshetko O.V., Denisov L.N., Gordeev I.G., Davydova A.F., Eremina N.A., Zemerova E.V., Ivanova T.B., Kastanayan A.A., Pokrovskaya T.G., Smakotina S.A., Smolyarchuk E.A., Artemyeva A.V., Ivanov R.A., Usacheva Yu.V., Chernyaeva E.V. THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL. Rheumatology Science and Practice. 2017;55(4):351-359. (In Russ.) https://doi.org/10.14412/1995-4484-2017-351-359
Email this article 